Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor Dismissal - The dismissal of Grant Thornton was linked to unresolved issues regarding segment reporting and internal controls, which the auditor communicated to management and the Audit Committee [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and indicated ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor, Grant Thornton, due to unresolved matters regarding segment reporting and internal controls [5] - Following the impairment charge and auditor dismissal, the stock price fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition Details - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, which was expected to double its total addressable market and significantly contribute to sales [2][3]. Financial Reporting Issues - The company claimed effective internal controls over financial reporting; however, it appears that it struggled with the integration of Pro-ficiency and lacked effective internal controls [3]. Stock Performance - Following the announcement of disappointing preliminary financial results for Q3 2025, Simulations Plus's stock fell by $6.39, or over 24%, from $26.44 to $20.05 per share [4]. - After reporting a $77.2 million charge related to prior acquisitions and dismissing its auditor Grant Thornton, the stock further declined by $4.50, nearly 26%, from $17.47 to $12.97 per share [5]. Auditor's Findings - Grant Thornton identified unresolved issues regarding segment reporting and internal controls, which contradicted Simulations Plus's statements about its financial reporting [5].

Core Insights - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial disclosures and issues with internal controls [1][3]. Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. Acquisition and Integration Issues - In June 2024, Simulations Plus acquired Pro-ficiency Holdings, Inc., claiming the acquisition would double its total addressable market and significantly contribute to sales [2][3]. - However, the company appears to have struggled with the integration of Pro-ficiency and lacked effective internal controls over financial reporting [3]. Financial Performance and Stock Impact - On June 11, 2025, Simulations Plus announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4]. - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 results, and subsequently dismissed its auditor, Grant Thornton, due to unresolved issues regarding segment reporting and internal controls [5]. - Following these revelations, the stock price fell nearly 26% from $17.47 to $12.97 per share [5].

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus reported challenges in integrating Pro-ficiency and acknowledged ineffective internal controls over financial reporting [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing the decline to market uncertainties, leading to a stock price drop of over 24% [4] - The company reported a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results and dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported disappointing preliminary financial results for Q3 2025, citing market uncertainties as significant headwinds, leading to a stock price drop of over 24% [4] - The company announced a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results, which contributed to a further decline in stock price of nearly 26% [5] - The dismissal of Grant Thornton LLP as the company's auditor raised concerns about internal controls and segment reporting, with the auditor identifying unresolved issues [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls, but evidence suggests struggles with integration and control effectiveness [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]